Better understanding of the genetic background of these extracolonic features, as well as the biological relevance of the signaling pathways behind them, may promote treatment options not only for cancer prevention but also for the other clinical features that may pose a significant morbidity and clinical burden, such as SMAD4-associated HHT and APC-associated desmoid tumors. This evidence concerns the gene APC and hereditary hemorrhagic telangiectasia.